Sorić Hosman Iva, Cvitković Roić Andrea, Lamot Lovro
Department of Pediatrics, Zadar General Hospital, Zadar, Croatia.
Department of Nephrology and Urology, Clinic for Pediatric Medicine Helena, Zagreb, Croatia.
Front Med (Lausanne). 2022 Jul 4;9:931717. doi: 10.3389/fmed.2022.931717. eCollection 2022.
Recurrent urinary tract infections (rUTI) represent a major healthcare and economic burden along with a significant impact on patient's morbidity and quality of life, even in the absence of well-known risk factors, such as vesicoureteral reflux. Despite numerous attempts to find a suitable therapeutic option, there is no clear benefit of any currently available intervention for prevention of UTI recurrence and its long-term consequences such as hypertension, renal scarring and/or insufficiency. The common treatment practice in many centers around the globe involves the use of continuous low-dose antibiotic prophylaxis, irrespective of various studies indicating increased microbial resistance against the prophylactic drug, leading to prolonged duration and escalating the cost of UTI treatment. Moreover, the rapid appearance of multi-drug resistant uropathogens is threatening to transform UTI to untreatable disease, while impaired host-microbiota homeostasis induced by a long-term use of antibiotics predisposes patients for various autoimmune and infectious diseases. New biomarkers of the increased risk of UTI recurrence could therefore assist in avoiding such outcomes by revealing more specific patient population which could benefit from additional interventions. In this light, the recent findings suggesting a crucial role of urothelial innate immunity mechanisms in protection of urinary tract from invading uropathogens might offer new diagnostic, prognostic and even therapeutic opportunities. Uroepithelial cells detect uropathogens pattern recognition receptors, resulting in activation of intracellular signaling cascade and transcription factors, which ultimately leads to an increased production and secretion of chemokines, cytokines and antimicrobial peptides into the urinary stream. Emerging evidence suggest that the disturbance of a single component of the urinary tract innate immunity system might increase susceptibility for rUTI. The aim of the current review is to update clinicians and researchers on potential biomarkers of host immune response alterations predisposing for rUTI and propose those well worth exploring further. For this purpose, over a hundred original papers were identified through an extensive PubMed and Scopus databases search. This comprehensive review might enrich the current clinical practice and fill the unmet clinical needs, but also encourage the development of therapeutic agents that would facilitate urinary bacterial clearance by enhancing the host immune response.
复发性尿路感染(rUTI)是一项重大的医疗和经济负担,对患者的发病率和生活质量有显著影响,即便不存在诸如膀胱输尿管反流等众所周知的风险因素。尽管人们多次尝试寻找合适的治疗方案,但目前任何可用的干预措施对于预防UTI复发及其长期后果(如高血压、肾瘢痕形成和/或肾功能不全)均无明显益处。全球许多中心的常见治疗方法是使用持续低剂量抗生素预防,尽管有各种研究表明对预防性药物的微生物耐药性增加,这导致UTI治疗时间延长且成本不断上升。此外,多重耐药尿路病原体的迅速出现有可能使UTI转变为无法治疗的疾病,而长期使用抗生素导致的宿主 - 微生物群稳态受损使患者易患各种自身免疫性疾病和感染性疾病。因此,UTI复发风险增加的新生物标志物可通过揭示更特定的可能从额外干预措施中获益的患者群体,帮助避免此类后果。有鉴于此,最近的研究结果表明尿路上皮固有免疫机制在保护尿路免受入侵尿路病原体侵害方面起关键作用,这可能提供新的诊断、预后甚至治疗机会。尿上皮细胞通过模式识别受体检测尿路病原体,导致细胞内信号级联和转录因子激活,最终导致趋化因子、细胞因子和抗菌肽在尿流中的产生和分泌增加。新出现的证据表明,尿路固有免疫系统单一成分的紊乱可能会增加rUTI的易感性。本综述的目的是向临床医生和研究人员介绍易患rUTI的宿主免疫反应改变的潜在生物标志物,并提出那些非常值得进一步探索的生物标志物。为此,通过广泛搜索PubMed和Scopus数据库确定了一百多篇原始论文。这一全面综述可能会丰富当前的临床实践并满足未满足的临床需求,还会鼓励开发通过增强宿主免疫反应来促进尿路细菌清除的治疗药物。